<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2705257464
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LANTUS SOLOSTAR 100I.U-ML DISPOSABLE PEN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INSULIN GLARGINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        296.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="sanofi-aventis" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10AE04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lantus contains insulin glargine. This is a modified insulin, very similar to human insulin.<br />Lantus is used to treat diabetes mellitus in adults, adolescents and children aged 2 years and above. Diabetes mellitus is a disease where your body does not produce enough insulin to control the level of blood sugar. Insulin glargine has a long and steady blood-sugar-lowering action.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Lantus<br />- If you are allergic to insulin glargine or to any of the other ingredients of this medicine (listed in section 6).<br />Warnings and precautions<br />Lantus in pre-filled pen is only suitable for injecting just under the skin (see also section 3). Speak to your doctor if you need to inject your insulin by another method.<br />Talk to your doctor, pharmacist or nurse before using Lantus.<br />Follow closely the instructions for posology, monitoring (blood and urine tests), diet and physical activity (physical work and exercise), injection technique as discussed with your doctor.<br />If your blood sugar is too low (hypoglycaemia), follow the guidance for hypoglycaemia (see box at the end of this leaflet).<br />Skin changes at the injection site<br />The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work very well if you inject into a lumpy area (see How to use Lantus). Contact your doctor if you are currently injecting into a lumpy area before you start injecting in a different area. Your doctor&nbsp;may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.<br />Travel<br />Before travelling consult your doctor. You may need to talk about<br />- the availability of your insulin in the country you are visiting,<br />- supplies of insulin, needles etc.,<br />- correct storage of your insulin while travelling,<br />- timing of meals and insulin administration while travelling,<br />- the possible effects of changing to different time zones,<br />- possible new health risks in the countries to be visited,<br />- what you should do in emergency situations when you feel unwell or become ill.<br />Illnesses and injuries<br />In the following situations, the management of your diabetes may require a lot of care (for example, adjustment to insulin dose, blood and urine tests):<br />- If you are ill or have a major injury then your blood sugar level may increase (hyperglycaemia).<br />- If you are not eating enough your blood sugar level may become too low (hypoglycaemia).<br />In most cases you will need a doctor. Make sure that you contact a doctor early.<br />If you have type 1 diabetes (insulin dependent diabetes mellitus), do not stop your insulin and continue to get enough carbohydrates. Always tell people who are caring for you or treating you that you require insulin.<br />Insulin treatment can cause the body to produce antibodies to insulin (substances that act against insulin). However, only very rarely, this will require a change to your insulin dose.<br />Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone (oral anti-diabetic medicine used to treat type 2 diabetes mellitus) and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).<br />Children<br />There is no experience with the use of Lantus in children below the age of 2 years.<br />Other medicines and Lantus<br />Some medicines cause changes in the blood sugar level (decrease, increase or both depending on the situation). In each case, it may be necessary to adjust your insulin dose to avoid blood sugar levels that are either too low or too high. Be careful when you start or stop taking another medicine.<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Before taking a medicine ask your doctor if it can affect your blood sugar level and what action, if any, you need to take.<br />Medicines that may cause your blood sugar level to fall (hypoglycaemia) include:<br />- all other medicines to treat diabetes,<br />- angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure),<br />- disopyramide (used to treat certain heart conditions),<br />- fluoxetine (used to treat depression),<br />- fibrates (used to lower high levels of blood lipids),<br />- monoamine oxidase (MAO) inhibitors (used to treat depression),&nbsp;pentoxifylline, propoxyphene, salicylates (such as acetylsalicylic acid, used to relieve pain and lower fever),<br />- sulfonamide antibiotics.<br />Medicines that may cause your blood sugar level to rise (hyperglycaemia) include:<br />- corticosteroids (such as &quot;cortisone&quot; used to treat inflammation),<br />- danazol (medicine acting on ovulation),<br />- diazoxide (used to treat high blood pressure),<br />- diuretics (used to treat high blood pressure or excessive fluid retention),<br />- glucagon (pancreas hormone used to treat severe hypoglycaemia),<br />- isoniazid (used to treat tuberculosis),<br />- oestrogens and progestogens (such as in the contraceptive pill used for birth control),<br />- phenothiazine derivatives (used to treat psychiatric disorders),<br />- somatropin (growth hormone),<br />- sympathomimetic medicines (such as epinephrine [adrenaline], salbutamol, terbutaline used to treat asthma),<br />- thyroid hormones (used to treat thyroid gland disorders),<br />- atypical antipsychotic medicines (such as clozapine, olanzapine),<br />- protease inhibitors (used to treat HIV).<br />Your blood sugar level may either rise or fall if you take:<br />- beta-blockers (used to treat high blood pressure),<br />- clonidine (used to treat high blood pressure),<br />- lithium salts (used to treat psychiatric disorders).<br />Pentamidine (used to treat some infections caused by parasites) may cause hypoglycaemia which may sometimes be followed by hyperglycaemia.<br />Beta-blockers like other sympatholytic medicines (such as clonidine, guanethidine, and reserpine) may weaken or suppress entirely the first warning symptoms which help you to recognise a hypoglycaemia.<br />If you are not sure whether you are taking one of those medicines ask your doctor or pharmacist.<br />Lantus with alcohol<br />Your blood sugar levels may either rise or fall if you drink alcohol.<br />Pregnancy and breast-feeding<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Inform your doctor if you are planning to become pregnant, or if you are already pregnant. Your insulin dose may need to be changed during pregnancy and after giving birth. Particularly careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby.<br />If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.<br />Driving and using machines<br />Your ability to concentrate or react may be reduced if:<br />- you have hypoglycaemia (low blood sugar levels),<br />- you havehyperglycaemia (high blood sugar levels),<br />- you have problems with your sight.</p><p>Keep this possible problem in mind in all situations where you might put yourself and others at risk (such as driving a car or using machines). You should contact your doctor for advice on driving if:<br />- you have frequent episodes of hypoglycaemia,<br />- the first warning symptoms which help you to recognise hypoglycaemia are reduced or absent.<br />Important information about some of the ingredients of Lantus<br />This medicine contains less than 1 mmol (23 mg) sodium per dose, i.e. it is essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.<br />Although Lantus contains the same active substance as Toujeo (insulin glargine 300 units/ml), these medicines are not interchangeable. The switch from one insulin therapy to another requires medical prescription, medical supervision and blood glucose monitoring. Please, consult your doctor for further information.<br />Dose<br />Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will<br />- determine how much Lantus per day you will need and at what time.<br />- tell you when to check your blood sugar level, and whether you need to carry out urine tests,<br />- tell you when you may need to inject a higher or lower dose of Lantus.<br />Lantus is a long-acting insulin. Your doctor may tell you to use it in combination with a short-acting insulin or with tablets used to treat high blood sugar levels.<br />Many factors may influence your blood sugar level. You should know these factors so that you are able to react correctly to changes in your blood sugar level and to prevent it from becoming too high or too low. See the box at the end of this leaflet for further information.<br />Use in children and adolescents<br />Lantus can be used in adolescents and children aged 2 years and above. Use this medicine exactly as your doctor has told you.<br />Frequency of administration<br />You need one injection of Lantus every day, at the same time of the day.<br />Method of administration<br />Lantus is injected under the skin. Do NOT inject Lantus in a vein, since this will change its action and may cause hypoglycaemia.<br />Your doctor will show you in which area of the skin you should inject Lantus. With each injection, change the puncture site within the particular area of skin that you are using.How to handle SoloStar<br />SoloStar is a pre-filled disposable pen containing insulin glargine. Lantus in pre-filled pen is only suitable for injecting just under the skin. Speak to your doctor if you need to inject your insulin by another method.<br />Read carefully the &quot;SoloStar Instructions for Use&quot; included in this package leaflet. You must use the pen as described in these Instructions for Use.<br />A new needle must be attached before each use. Only use needles that are compatible for use with SoloStar (see &ldquo;SoloStar Instructions for Use&rdquo;).<br />A safety test must be performed before each injection.<br />Look at the cartridge before you use the pen. Do not use SoloStar if you notice particles in it. Only use SoloStar if the solution is clear, colourless and waterlike. Do not shake or mix it before use.<br />To prevent the possible transmission of disease, never share your pen with anyone else. This pen is only for your use.<br />Make sure that neither alcohol nor other disinfectants or other substances contaminate the insulin.<br />Always use a new pen if you notice that your blood sugar control is unexpectedly getting worse. If you think you may have a problem with SoloStar, consult your doctor, pharmacist or nurse.<br />Empty pens must not be re-filled and must be properly discarded.<br />Do not use SoloStar if it is damaged or not working properly, it has to be discarded and a new SoloStar has to be used.<br />Insulin mix-ups<br />You must always check the insulin label before each injection to avoid mix-ups between Lantus and other insulins.<br />If you use more Lantus than you should<br />&minus; If you have injected too much Lantus, your blood sugar level may become too low (hypoglycaemia). Check your blood sugar frequently. In general, to prevent hypoglycaemia you must eat more food and monitor your blood sugar. For information on the treatment of hypoglycaemia, see box at the end of this leaflet.<br />If you forget to use Lantus<br />&minus; If you have missed a dose of Lantus or if you have not injected enough insulin, your blood sugar level may become too high (hyperglycaemia). Check your blood sugar frequently. For information on the treatment of hyperglycaemia, see box at the end of this leaflet.<br />&minus; Do not take a double dose to make up for a forgotten dose.<br />If you stop using Lantus<br />This could lead to severe hyperglycaemia (very high blood sugar) and ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). Do not stop Lantus without speaking to a doctor, who will tell you what needs to be done.<br />If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If you notice signs of you blood sugar being too low (hypoglycaemia), take action to increase your blood sugar level straight away (see the box at the end of this leaflet). Hypoglycaemia (low blood sugar) can be very serious and is very common with insulin treatment (may affect more than 1 in 10 people). Low blood sugar means that there is not enough sugar in your blood. If your blood sugar level falls too low, you may pass out (become unconscious). Serious hypoglycaemia may cause brain damage and may be life-threatening. For more information, see the box at the end of this leaflet.<br />Severe allergic reactions (rare, may affect up to 1 in 1,000 people) &ndash; the signs may include large-scale skin reactions (rash and itching all over the body), severe swelling of skin or mucous membranes (angiooedema), shortness of breath, a fall in blood pressure with rapid heart beat and sweating.Severe allergic reactions to insulins may become life-threatening. Tell a doctor straight away if you notice signs of severe allergic reaction.<br />Common reported side effects (may affect up to 1 in 10 people)<br />&bull; Skin changes at the injection site<br />If you inject your insulin too often at the same skin site, fatty tissue under the skin at this site may either shrink (lipoatrophy, may affect up to 1 in 100 people) or thicken (lipohypertrophy). The insulin may not work very well. Change the injection site with each injection to help prevent these skin changes.<br />&bull; Skin and allergic reactions at the injection site<br />The signs may include reddening, unusually intense pain when injecting, itching, hives, swelling or inflammation. This can spread around the injection site. Most minor reactions to insulins usually disappear in a few days to a few weeks.<br />Rare reported side effect (may affect up to 1 in 1,000 people)<br />&bull; Eye reactions<br />A marked change (improvement or worsening) in your blood sugar control can disturb your vision temporarily. If you have proliferative retinopathy (an eye disease related to diabetes) severe hypoglycaemic attacks may cause temporary loss of vision.<br />&bull; General disorders<br />In rare cases, insulin treatment may also cause temporary build-up of water in the body, with swelling in the calves and ankles.<br />Very rare reported side-effects (may affect up to 1 in 10,000 people)<br />In very rare cases, dysgeusia (taste disorders) and myalgia (muscular pain) can occur.<br />Use in children and adolescents<br />In general, the side effects in children and adolescents of 18 years of age or less are similar to those seen in adults.<br />Complaints of injection site reactions (injection site reaction, injection site pain) and skin reactions (rash, urticaria) are reported relatively more frequently in children and adolescents of 18 years of age or less than in adults.<br />There is no experience in children under 2 years.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in the end of this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.To reports any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton and on the label of the pen after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.<br />Not in-use pens<br />Store in a refrigerator (2&deg;C-8&deg;C). Do not freeze or place next to the freezer compartment or a freezer pack.<br />Keep the pre-filled pen in the outer carton in order to protect from light.<br />In use pens<br />Pre-filled pens in use or carried as a spare may be stored for a maximum of 4 weeks not above 30&deg;C and away from direct heat or direct light.The pen in use must not be stored in the refrigerator Do not use it after this time period.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is insulin glargine. Each ml of the solution contains 100 units of insulin glargine (equivalent to 3.64 mg).<br />- The other ingredients are: zinc chloride, metacresol, glycerol, sodium hydroxide (see section 2 &ldquo;Important information about some of the ingredients of Lantus) and hydrochloric acid (for pH adjustment) and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen is a clear and colourless solution. Each pen contains 3 ml of solution for injection (equivalent to 300 units).
Pack sizes of 5 pre-filled pens.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong><br />Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt am Main, Germany.<br /><strong>Secondary Packaging:</strong><br />Sanofi-Aventis Arabia co. LTD<br />KSA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي لانتوس على أنسولين غلارجين. إنه أنسولين معدّل شبيه جداً بالأنسولين البشري.<br />يُستعمل لانتوس لعلاج داء السكّري لد ى البالغين والمراهقين والأطفال ابتداء من سنّ الثانية. داء السكري هو مرض لا يفرز فيه<br />الجسم ما يكفي من الأنسولين للتحكّم بمعدل السكر في الدم )سكّر الدم(. يخفّض الأنسولين غلارجين سكر الدم بشكل مطوّل ومنتظم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع الاستعما ل<br />لا تستعمل لانتو س<br />- إن كان لديك حساسية تجاه الأنسولين غلارجين أو تجاه أحد مكوّنات هذا الدواء الأخرى )المذكورة في القسم 6 .)<br />تحذيرات واحتياطات مع لانتو س<br />يجب استعمال لانتوس في قلم معبّأ مسبقًا تحت الجلد حصرًا )راجع أيض اً القسم 3 (. إذا كنت تحتاج إلى حقن الأنسولين بطريقة<br />أخرى، الرجاء استشارة طبيبك.<br />إستشر الطبيب أو الصيدلي أو الممرّض/ة قبل استعمال لانتوس.<br />الرجاء أن تتقيّد بدقة بتعليمات الطبيب المتعلقة بمقدار الجرعة والمراقبة )فحوصات الدم والبول( والنظام الغذائي والنشاط الجسدي<br />)العمل الجسدي والتمارين الرياضية( وتقنيّة الحقن.<br />إذا كان معدّل السكر في دمك منخفضً ا )نقص سكر الدم(، اتبع التعليمات الخاصة بنقص سكر الدم )راجع الإطار في نهاية هذه<br />النشرة(.<br />تغيّر الجلد في موقع ال حقن<br />يجب تغيير موقع الحقن لمنع تغيّر الجلد مثل تشكّل كتل تحت الجلد. قد لا يعطي الأنسولين مفعوله كما يجب إذا حقنته في منطقة تشكل<br />الكتل )راجع كيف يستعمل لانتوس(. اتّصل بالطبيب إذا كنت تحقن حاليًّا في منطقة تتشكل فيها الكتل قبل أن تبدأ بالحقن في منطقة<br />مختلفة. قد يطلب منك الطبيب مراقبة السكر في دمك بدقّة وتعديل جرعة الأنسولين أو جرعة الأدوية المضادة للسكّ ري الأخرى.السفر<br />قبل أن تسافر، إستشر طبيبك ليعلمك بالنقاط الآتية:<br />- توافر الأنسولين الذي تستعمله في البلد الذي تزوره،<br />- التزوّد بالأنسولين، بالإبر، إلخ.<br />- الطريقة الصحيحة لحفظ الأنسولين خلال السفر،<br />- توقيت الوجبات وأخذ الأنسولين خلال السفر،<br />- التأثيرات الممكنة الناتجة عن التغيير إلى مناطق زمنية مختلفة،<br />- المخاطر الصحية الجديدة المحتملة في البلدان التي ستزورها،<br />- ما عليك فعله في الحالات الطارئة التي تشعر فيها بالتوعّك أو بالمرض.<br />الأمراض والجروح<br />في الحالات الآتية، قد يتطلّب علاج داء السكري الذي تعاني منه الكثير من الحذر )مثلاً ضبط جرعة الأنسولين، فحوصات الدم<br />والبول(:<br />- إذا كنت مريضاً أو مجروحًا جرحًا كبيرًا، من الممكن أن يرتفع معدّل السكر في دمك )فرط سكر الدم( .<br />- إذا كنت لا تتناول كمية كافية من الطعام، قد ينخفض كثيراً معدل السكر في دمك )نقص سكر الدم( .<br />ستحتاج إلى طبيب في أكثر الحالات. إحرص على الاتصال سريع ا بطبي ب .<br />إذا كنت تعاني من داء السكري من النوع 1 )داء السكري المعتمد على الأنسولين(، لا توقف أخذ الأنسولين وتابعه حتى تحصل على<br />كمية كافية من الكربوهيدرات. قل دائماً للأشخاص الذين يعتنون بك أو يعالجونك إنك تحتاج إلى الأنسولين.<br />يمكن أن يسبّب العلاج بالأنسولين إنتاج أجسام مض ادة )مواد مضادة للأنسولين(. ولكن لن يكون تغيير جرعة الأنسولين ضروريًا إلاّ<br />في حالات نادرة جدًا.<br />أُصيب بعض المرضى الذين يعانون من داء السكري من النوع 2 منذ وقت طويل والذين يعانون من مرض قلبي أو تعرّضوا في<br />السابق لحادث مخيّ وعائي ويُعالجون بالبيوغليتازون )دواء فموي مضاد للسكّري يُستعمل لعلاج داء السكّري من النوع 2 )<br />والأنسولين، بقصور قلبي. إذا أصبت بأعراض القصور القلبي مثل ضيق نفس غير عادي أو زيادة وزن سريعة أو تورّم موضعي<br />)أوديما(، أعلم طبيبك في أقرب وقت ممكن.<br />الأطفال<br />لم تتمّ دراسة لانتوس لدى الأطفال ما دون الثانية من العمر.<br />أدوية أخرى ولانتو س<br />يسبّب بعض الأدوية تعديل معدل سكر الدم )انخفاض أو ارتفاع في معدّل سكّر الدم أو التأثيران معًا حسب الحالة(. في كل حالة، قد<br />يكون من الضروري ضبط جرعة الأنسولين التي ت أخذها ل تفادي معدلات السكر المنخفضة جد اً أو المرتفعة جداً. فكن حذراً عندما تبدأ<br />علاجً ا آخر أو عندما توقفه كذلك.<br />إذا كنت تأخذ أو أخذت مؤخّرًا أو قد تأخذ دواء آخر، أعلم الطبيب أو الصيدلي. وقبل أن تتناول أيّ دواء، اسأل طبيبك إن كان يمكن<br />أن يؤثّر هذا الدواء على معدل السكر في دمك وعن أيّ إجراء عليك اتخاذه عند الاقتضاء.<br />الأدوية التي قد تسبب انخفاض ا في معدل السكر في دمك )نقص سكر الدم( تتضمّن :<br />كافة الأدوية الأخرى لعلاج السكري، -<br />مثبطات الأنزيم المحوّل للأنجيوتنسين )المستعملة لعلاج بعض الأمراض القلبيّة أو ارتفاع ضغط الدم الشرياني(، -<br />الديزوبيراميد )المستعمل لعلاج بعض الأمراض القلبيّة(، -<br />الفليوكسيتين )المستعمل لعلاج الاكتئاب(، -<br />أدوية الفيبرات )المستعملة لتخفيض معدّلات الدهون المرتفعة في الدم(، -<br />مثبطات أكسيداز الأمين الأحادي )المستعملة لعلاج الاكتئاب(، -<br />البنتوكسيفيلين والبروبوكسيفين والساليسيلات )مثل حمض أسيتيل الساليسيليك المستعمل لتخفيف الألم وتخفيض الحرارة(، -<br />المضادات الحيوية من عائلة السلفوناميد. -<br />الأدوية التي قد تسبب ارتفاع ا في معدل السكر في دمك )فرط سكر الدم( تتضمّن :<br />- الستيرويدات القشريّة )مثل &quot;الكورتيزون&quot; المستعمل لعلاج الالتهاب( ،<br />- الدانازول )دواء يعمل على الإباضة(،<br />- الديازوكسيد )المستعمل لعلاج فرط الضغط الشرياني(،<br />- مدرّات البول )المستعملة لعلاج فرط الضغط الشرياني أو الاحتباس المفرط للسوائل(،<br />- الغلوكاغون )هورمون بنكرياسي يُستعمل لعلاج ح الات نقص سكر الدم الحادة(،<br />- الإيزونيازيد )المستعمل لعلاج مرض السل( ،الاستروجين والبرجستوجين )مثلاً في حبة منع الحمل(،<br />- مشتقات الفينوتيازين )المستعملة لعلاج الأمراض النفسيّة( ،<br />- السوماتروبين )هورمون النمو( ،<br />- المقلدات الودية )مثلاً إيبينفرين ]أدرينالين[ وسالبوتامول وتربوتالين المستعملة لعلاج الربو( ،<br />- الهورمونات الدرقية )المستعملة لعلاج خلل وظيفة الغدة الدرقيّة(،<br />- مضادات الذهان اللانمطيّة )مثل الأولنزبين والكلوزابين(،<br />- مثبّطات البروتياز )المستعملة لعلاج فيروس نقص المناعة البشرية( .<br />قد ينخفض معدّل السكر في دمك أو يرتفع إذا أخذ ت:<br />- حاصرات البيتا )المستعملة لعلاج فرط ضغط الدم الشرياني(،<br />- الكلونيدين )المستعمل لعلاج فرط ضغط الدم الشرياني(،<br />- أملاح الليثيوم )المستعملة لعلاج الأمراض النفسيّة( .<br />وقد يسبب البنتاميدين )المستعمل لعلاج بعض حالات العدوى التي تسببها طفيليّات( نقص سكر الدم ويتبعه أحياناً فرط سكر الدم.<br />إن حاصرات البيتا كالمقلدات الودية الأخرى )مثل كلونيدين وغوانيثيدين وريزيربين( قد تضعف أعراض التحذير عند حصول نقص<br />في سكر الدم أو قد تخمدها تماما .<br />إذا كان لديك شكّ حول نوع الأدوية التي تستعمله ا، إسأل طبيبك أو الصيدلي.<br />لانتوس مع الكحو ل<br />قد يرتفع معدّل السكر في دمك أو ينخفض إذا شربت الكحول.<br />الحمل و الإرضا ع<br />إستشيري الطبيب أو الصيدلي قبل تناول أيّ الدواء.<br />أعلمي طبيبك إن كنت تنوين الحمل أو إن كنت حاملاً. قد يكون من الضروري تعديل جرعة الأنسولين التي تأخذينها خلال الحمل<br />وبعد الولادة. إن التحكّم الدقيق بداء السكري الذي تعانين منه والوقاية من نقص سكر الدم مهمّان لصحة طفلك.<br />إن كنت تُرضعين، استشيري طبيبك لأنك قد تحتاجين إلى تعديل في جرعات الأنسولين ونظامك الغذائي.<br />قيادة السيارات واستعمال الآلا ت<br />إن قدرتك على التركيز أو التفاعل قد تضعف إذا:<br />- كنت مصابًا بنقص سكر الدم )معدّل منخفض لسكر الدم( ؛<br />- كنت مصابًا بفرط سكر الدم )معدّل مرتفع لسكر الدم( ؛<br />- كنت تعاني من مشاكل في البصر.<br />الرجاء أن تبقي هذه الإمكانيّة في ذهنك في كافة الحالات التي قد تعرّض فيها نفسك والآخرين للخطر )مث لاً قيادة سيارة أو تشغيل<br />آلات(. يجب عليك استشارة طبيبك حول قدرتك على القيادة في حال:<br />- كنت تتعرّض لنوبات متكررة من نق ص سكر الدم،<br />- كانت أعراض التحذير الأولى التي تساعدك على التعرّف إلى نقص سكّر الدم ضعيفة أو غائبة.<br />معلومات مهمّة تتعلق ببعض مكوّنات لانتو س<br />يحتوي هذا الدواء على أقلّ من ملمول واحد ) 23 ملغ( من الصوديوم في الجرعة الواحدة وبالتالي يُعتبر &quot; خاليًا من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحرص دائمًا على استعمال هذا الدواء بالتقيّد التام بتعليمات طبيبك.<br />تأكّد من الطبيب أو من الصيدليّ في حال الشكّ.<br />حتّى ولو كان لانتوس يحتوي على المادة الفعالة ذاتها التي يحتوي عليها توجيو )أنسولين غلارجين 300 وحدة/مل(، هذان الدواءان<br />ليسا قابلين للتبادل. فاستبدال أنسولين بأنسولين آخر، يتطلّب وصفة طبيّة ومراقبة طبيّة ومراقبة لسكّر الدم. الرجاء استشارة الطبي ب<br />للحصول على المزيد من المعلومات.<br />مقدار الجرع ة<br />استناداً إلى أسلوب حياتك ونتائج فحوصات معدل السكر )الغلوكوز( في دمك واستعمالك السابق للأنسولين، فإن طبيبك سوف:<br />- يحدد الجرعة اليوميّة الضروريّة من لانتوس ووقت الحقن؛<br />- يقول لك متى عليك التحكّم بمعدل السكر في دمك وإن كنت تحتاج إلى إجراء فحوصات بول؛يقول لك متى قد تحتاج إلى حقن جرعة أعلى أو أدنى من لانتوس . -<br />إن لانتوس هو أنسولين طويل المفعول. عند الحاجة، سيصف لك الطبيب استعماله بالتزامن مع أنسولين قصير المفعول أو مع أقراص<br />مخفّضة لسكّر الدم.<br />قد تؤثّر عوامل كثيرة على معدل السكر في دمك. يجب عليك أن تعرف هذه العوامل لكي تكون قادراً على التصرّف بطريقة صحيحة<br />حيال التغييرات في معدل السكر في دمك فتمن ع ارتفاعه أو انخفاضه كثيراً. راجع الإطار في نهاية النشرة للمزيد من المعلومات .<br />الاستعمال لدى الأطفال والمراهقي ن<br />يمكن استعمال لانتوس لدى المراهقين والأطفال ابتداء من سنّ الثانية. استعمل دائمًا هذا الدواء بالتقيّد تمامًا بتعليمات طبيبك.<br />عدد مرّات الاستعما ل<br />تحتاج إلى حقنة واحدة من لانتوس يوميًا وفي الوقت نفسه كلّ يوم.<br />طريقة الاستعما ل<br />يُحقن لانتوس تحت الجلد. لا تحقن أبد اً لانتوس في الوريد لأنّ ذلك يغيّر فعله ويمكن أن يسبّب نقصًا في سكّر الدم.<br />سوف يعيّن لك طبيبك المنطقة الجلديّة الّتي يجب أن ت حقن لانتوس فيه ا. مع كل حقن ة أنسولين، غيّر موقع الوخز ضمن المنطقة<br />المحددة من الجلد التي تستعملها.<br />كيفية استعمال سولوستا ر<br />سولوستار هو قلم معبّأ مسبقاً يحتوي على الأنسولين غلارجين ويُرمى بعد الاستعمال.<br />يجب حقن لانتوس في قلم معبّأ مسبقًا تحت الجلد حصرًا. إذا كنت تحتاج إلى حقن الأنسولين بطريقة أخرى، الرجاء الاتصال بطبيبك.<br />إقرأ بدقة &quot;تعليمات استعمال سولوستار&quot; التي تتضمّنها هذه ا لنشرة. يجب عليك استعمال قلم الحقن حسب الوصف الوارد في<br />تعليمات الاستعمال هذه .<br />يجب تعليق إبرة جديدة قبل كل استعمال. لا تستعمل إلاّ الإبر الموافق عليها للاستعمال مع سول وستار )راجع فقرة &quot;تعليمات استعمال<br />سولوستار&quot;( .<br />يجب إجراء اختبار سلامة قبل كل عملية حقن.<br />عاين الخرطوشة قبل أن تستعمل قلم الحقن. لا تستعمل سول وستار إذا لاحظت وجود جسيمات فيه. لا تستعمل سول وستار إلاّ إذا كان<br />المحلول صافياً وبدون لون وسائلاً مثل الماء. لا ترجّه أو تمزجه قبل الاستعمال.<br />لتفادي إمكانية إنتقال الأمراض، لا تقم بإعارة قلمك إل ى أيّ أحد آخر. فهذا القلم مخصص لك شخصيًا.<br />تأكّد من أن لا الكحول ولا أيّ مطهرات أخرى أو مواد أخرى تلوّث الأنسولين .<br />استعمل دائماً قلم حقن جديد اً إذا لاحظت أن التحكّم بمعدل السكر في دمك يزداد سوءاً بشكل غير متوقّع. إن كنت تعتقد أنك تعاني من<br />مشكلة مع سولوستار، إستشر الطبيب أو الصيدلي أو الممرّض/ة .<br />يجب عدم إعادة تعبئة أقلام الحقن الفارغة بل يجب التخلّص منها بطريقة مناسبة.<br />لا تستعمل سولوستار إذا كان متضرراً أو لا يعمل بطريقة صحيحة )بسبب عيوب ميكانيكيّة(، يجب رميه ويجب استعمال سول وستار<br />جديد.<br />الخلط بين الأنسولينا ت<br />يجب عليك أن تتحقّق دائمًا من لصاقة الأنسولين قبل كلّ عمليّة حقن لتفادي الخلط بين لانتوس والأنسولينات الأخرى.<br />إذا أخذت كميّة من لانتوس أكبر من التي عليك أخذه ا<br />- إذا حقنت كمية كبيرة من لانتوس، قد ينخفض سكر الدم لديك كثيرًا )نقص سكّر الدم(. إفحص معدّل السكر في دمك تكراراً.<br />بصورة عامة، لتفادي نق ص سكر الدم، يجب عليك أن تأكل أكثر وتراقب معدّل السكر في دمك. لمزيد من المعلومات حول<br />معالجة نقص سكر الدم، راجع الإطار في نهاية هذه النشرة.<br />إذا نسيت أخذ لانتو س<br />- إذا فوتّ جرعة من لانتوس أو لم تحقن كميّة كافية من الأنسو لين، قد يرتفع كثيراً معدّل السكر في دم ك )فرط سكّر الدم(.<br />إفحص معدّل السكر في دمك تكراراً. للمزيد من المعلومات حول علاج فرط سكر الدم، راجع الإطار في نهاية هذه النشرة.<br />- لا تأخذ جرعة مزدوجة للتعويض عن الجرعة التي نسيت أخذه ا.إذا توقّفت عن استعمال لانتو س<br />يمكن أن يسبّب هذا فرط سكر دم حادًا )معدل مرتفع جدًا للسكر في الدم( وكثرة الحمضات )تكوّن الحمض في الدم عندما يفكّك الجسم<br />الدهون بدلاً من السكر(. لا تتوقّف عن استعمال لانتوس بدون استشارة الطبيب الذي سيقول لك ما عليك فعله .<br />إذا كان لديك أسئلة أخرى حول استعمال هذا الدواء، اطلب المزيد من المعلومات من الطبيب أو الصيدلي أو الممرّض/ة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية يمكن أن يسبّ ب هذا الدواء تأثيرات جانبيّة لا تصيب المرضى كلّهم.<br />إذا لاحظت إشارات تدلّ على أنّ معدّل السكّر في دمك منخفض ج دا )نقص سكّر الدم(، اتخذ الإجراءات المناسبة لكي تزيد معدّل<br />السكّر في دمك على الفور )راجع الإطار في نهاية هذه النشرة(. يمكن أن يكون نقص سكّر الدم )معدّل منخفض من السكّر في الدم(<br />خطيرًا جدًا وهو شائع جدًا عند العلاج بالأنسولين )يمكن أن يصيب أكثر من شخص من أصل 10 أشخاص(. يعني انخفاض معدّل<br />السكّر في الدم أنّ كميّة السكّر في دمك غير كافية. إذا كان معدّل السكّر في دمك منخفضًا جدًا، قد تفقد الوعي )يُ غمى عليك(. يمكن أن<br />يسبّب نقص سكّر الدم الحاد ضررًا في الدماغ ويمكن أن يشكّل خطرًا على الحياة. للمزيد من المعلومات، راجع الإطار في نهاية هذه<br />النشرة.<br />ارتكاسات تحسسيّة حادة )نادرة، يمكن أن تُصيب شخصً ا من أصل 1000 شخص كحدّ أقصى(<br />يمكن أن تتضمّن الأعراض ارتكاسات جلديّة منتشرة )طفح وحكّة في الجسم كلّه( وتورّمًا حادًا في الجلد أو في الأغشية المخاطيّة<br />)أوديما كوينك( وضيق نفس وانخفاض الضغط الشرياني مع ضربات قلب سريعة وتعرّق كثيف. يمكن أن تشكّل الارتكاسات<br />التحسسيّة الحادة تجاه الأنسولين خطرًا على الحياة. اتصل بطبيبك على الفور إذا لاحظت أعراض ارتكاسات تحسسيّة حادة.<br />&bull; تغيّر الجلد في موقع الحقن :<br />إذا حقنت الأنسولين لمرّات كثيرة في المكان ذاته من الجلد، يمكن أن ينكمش الجلد )الضمور الشحمي، يمكن أن يصيب لغاية شخص<br />واحد من أصل 100 ( أو أن يصبح أكثر سماكة )التضخّم الش حمي، يمكن أن يصيب لغاية شخص واحد من أصل 10 (. وكذلك يمكن<br />أن تتشكّل كتل تحت الجلد بسبب تراكم بروتين يُسمّى أميلويد )الداء النشواني الجلدي، عدد مرّات حصوله غير معروف(. قد لا يعطي<br />الأنسولين مفعوله كما يجب إذا كنت تحقنه في منطقة تتشكل فيها الكتل. غيّر موقع الحقن مع كلّ حقنة للمساعدة على منع حصول هذه<br />التغييرات الجلديّة.<br />التأثيرا ت الجانبيّة الشائعة )يمكن أن تصيب شخصًا من أصل 10 كحدّ أقصى(<br />&bull; ارتكاسات جلديّة وتحسسيّة في موقع الحقن<br />يمكن أن تتضمّن الأ عراض احمرارًا وألمًا حادًا بشكل غير اعتيادي عند الحقن وحكّة وشرى وتورّمًا والتهابًا. يمكن أن تنتشر هذه<br />الارتكاسات حول نقطة الحقن. عادة ما تختفي أكثريّة الارتكاسات البسيطة تجاه الأنسولين خلال بضعة أيّام إلى بضعة أسابيع.<br />التأثيرا ت الجانبيّة النادرة )يمكن أن تصيب شخصًا من أصل 1000 شخص كح دّ أقصى(<br />&bull; التأثيرا ت على البص ر<br />يمكن أن يسبّب تغيير كبير )تحسّن أو تدهور( في التحكّم بمعدّل السكر في دمك تدهوراً مؤقتاً في بصرك. إن كنت تعاني من اعتلال<br />شبكيّة العين المتكاثر )مرض في العين سببه داء السكري(، قد تسبب نوبات انخف اض سكر الدم فقدان اً مؤقتاً في البصر.<br />&bull; الاضطرابات العام ة<br />في حالات نادرة قد يسبّب العلاج ب الأنسولين كذلك إحتباساً مؤقتاً للماء في الجسم مع تورّم في الربلتين والكاحلين.<br />التأثيرا ت الجانبيّة النادرة ج دا )يمكن أن تصيب شخصًا من أصل 10000 شخص كحدّ أقصى(<br />في حالات نادرة جداً يمكن أن يُصاب المرضى بفقد المذاق )اضطرابات في حاسة الذوق( وبألم عضلي )وجع عضلي(.<br />الاستعمال لدى الأطفال والمراهقي ن<br />بصورة عامة، تتشابه التأثيرات الجانبيّة لدى الأطفال والمراهقين البالغين 18 عاماً وما دون مع تلك التي يُصاب بها البالغون.<br />عادة ما يُفاد أكثر عن شكاوى من الارتكاسات في موقع الحقن )ألم في موقع الحقن، ارتكاس في موقع الحقن( ومن الارتكاسات<br />الجلديّة )طفح، حكّة( لدى الأطفال والمراهقين البالغين 18 عاماً وما دون منه لدى المرضى البالغين.<br />لدى الأطفال ما دون الثانية من العمر، لم يتمّ تقييم استعمال هذا الدواء.<br />الإبلاغ عن التأثيرا ت الجانبيّ ة<br />إذا شعرت بأيّ تأثير جانبيّ، أعلم طبيبك أو الصيدليّ. ينطبق هذا أيضًا على أيّ تأثير جانبيّ غير مذكور في هذه النشرة.بالإبلاغ عن التأثيرات ال جانبيّة، تساهم في تزويد المزيد من المعلومات حول سلامة الدواء.<br />للإبلاغ عن أي أعراض جانبية :<br />&bull; المملكة العربية السعودية :<br />المركز الوطني للتيقظ والسلامة الدوائي ة -<br />&bull; الرقم المُوحّد للهيئة العامّة للغذاء والدّواء: 19999<br />&bull; البريد الالكتروني: npc.drug@sfda.gov.sa<br />&bull; الموقع الالكتروني: https://ade.sfda.gov.sa /<br />سانوفي للتيقظ الدوائي: KSA_Pharmacovigilance@sanofi.com5</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحفظ هذا الدواء بعيداً عن نظر الأطفال ومتناولهم .<br />لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المدوّن على العلبة وعلى لصاقة القلم بعد كلمة &laquo; EXP &raquo; . يشير تاريخ انتهاء<br />الصلاحيّة إلى اليوم الأخير من الشهر المذكور .<br />القلم قبل الاستعمال<br />إحفظه في البرّاد )م ا بين 2 و 8 درجة مئوية( .<br />لا تجمّ ده ولا تضعه قرب الثلاّجة أو حجرة تجميد.<br />إحفظ القلم المعبّأ مسبقاً في العبوة الخارجيّة بعيداً عن النور.<br />إذا كان القلم قيد الاستعمال<br />يمكن حفظ الأقلام المعبّأة مسبقًا التي هي قيد الاستعمال أو المنقولة للاحتياط حتّى أربعة أسابيع كحدّ أقصى في درجة حرارة لا<br />تتجاوز 30 درجة مئوية بعيداً عن مصدر حرارة أو عن مصدر نور مباشر. لا ينبغي حفظ القلم قيد الاستعمال في البرّاد. لا تستعمله<br />بعد انقضاء هذه المدة .<br />لا تقم برمي أيّ دواء في مياه الصرف الصحّي أو مع النفايات المنزليّة. إسأل الصيدلي حول كيفيّة التخلّص من الأدوية التي لم تعد<br />تستعمله ا. فمن شأن هذه الإجراءات أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي الأنسولين غلارجين. ي حتوي كلّ مل من المحلول على - 100 وحد ة من الأنسولين غلارجين )ما يساوي 3.64<br />ملغ(.<br />المكوّنات الأخرى هي: كلوريد الزنك، ميتاكريزول، غليسيرول، هيدروكسيد الصوديوم )راجع في القسم - 2 فقرة &quot;معلومات<br />مهمّة حول بعض مكوّنات لانتوس&quot;(، حمض الهيدروكلوريك )لضبط الرقم الهيدروجيني(، وماء لمستحضرات الحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما هو لانتوس ومحتوى العلبة الخارجيّ ة<br />محلول لانتوس سولوستار 100 وحدة/مل في قلم معبّأ مسبقاً هو محلول صاف وعديم اللون.<br />يحتوي كلّ قلم على 3 مل من محلول الحقن )ما يساوي 300 وحدة(.<br />يأتي في علب من 1 و 3 و 4 و 5 و 6 و 8 و 9 و 10 أقلام معبّأة مسبقاً.<br />قد لا تكون كلّ أحجام العلب مسوّقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>Sanofi-Aventis Deutschland GmbH<br />D-65926 Frankfurt am Main<br />Germany.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            دیسمبر 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains 100 units insulin glargine* (equivalent to 3.64 mg). Each pen contains 3 ml of solution for injection, equivalent to 300 units.
*Insulin glargine is produced by recombinant DNA technology in Escherichia coli. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection. Clear colourless solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Lantus contains insulin glargine, an insulin analogue, and has a prolonged duration of action. Lantus should be administered once daily at any time but at the same time each day.<br />The dose regimen (dose and timing) should be individually adjusted. In patients with type 2 diabetes mellitus, Lantus can also be given together with orally active antidiabetic medicinal products.<br />The potency of this medicinal product is stated in units. These units are exclusive to Lantus and are not the same as IU or the units used to express the potency of other insulin analogues (see<br />section 5.1).<br />Special population<br />Elderly population (&ge;65 years old)<br />In the elderly, progressive deterioration of renal function may lead to a steady decrease in insulin requirements.<br />Renal impairment<br />In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.<br />Hepatic impairment<br />In patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.</p><p>Paediatric population<br />&bull; Adolescents and children aged 2 years and older patients<br />Safety and efficacy of Lantus have been established in adolescents and children aged 2 years and older (see section 5.1). The dose regimen (dose and timing) should be individually adjusted.<br />&bull; Children below 2 years of age<br />The safety and efficacy of Lantus have not been established. No data are available. Transition from other insulins to Lantus<br />When changing from a treatment regimen with an intermediate or long-acting insulin to a regimen with Lantus, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast-acting insulin analogues or the dose of oral antidiabetic medicinal products).<br />To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with Lantus should reduce their daily dose of basal insulin by 20-30% during the first weeks of treatment.<br />During the first weeks the reduction should, at least partially, be compensated by an increase in mealtime insulin, after this period the regimen should be adjusted individually.<br />Patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with Lantus.<br />Close metabolic monitoring is recommended during the transition and in the initial weeks thereafter. With improved metabolic control and resulting increase in insulin sensitivity a further adjustment in<br />dose regimen may become necessary. Dose adjustment may also be required, for example, if the<br />patient&#39;s weight or life-style changes, change of timing of insulin dose or other circumstances arise that increase susceptibility to hypo- or hyperglycaemia (see section 4.4).<br />Method of administration<br />Lantus is administered subcutaneously.<br />Lantus should not be administered intravenously. The prolonged duration of action of Lantus is dependent on its injection into subcutaneous tissue. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia.<br />There are no clinically relevant differences in serum insulin or glucose levels after abdominal, deltoid or thigh administration of Lantus. Injection sites must be rotated within a given injection area from one injection to the next.<br />Lantus must not be mixed with any other insulin or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.<br />Before using SoloStar, the instructions for use included in the package leaflet must be read carefully (see section 6.6).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lantus is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, regular insulin administered intravenously is recommended in such cases.<br />56<br />In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient&#39;s adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.<br />Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, long-acting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose.</p><p>Hypoglycaemia<br />The time of occurrence of hypoglycaemia depends on the action profile of the insulins used and may, therefore, change when the treatment regimen is changed. Due to more sustained basal insulin supply with Lantus, less nocturnal but more early morning hypoglycaemia can be expected.<br />Particular caution should be exercised, and intensified blood glucose monitoring is advisable in patients in whom hypoglycaemic episodes might be of particular clinical relevance, such as in patients with significant stenoses of the coronary arteries or of the blood vessels supplying the brain (risk of cardiac or cerebral complications of hypoglycaemia) as well as in patients with proliferative retinopathy, particularly if not treated with photocoagulation (risk of transient amaurosis following hypoglycaemia).<br />Patients should be aware of circumstances where warning symptoms of hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be changed, be less pronounced or be absent in certain risk groups. These include patients:<br />- in whom glycaemic control is markedly improved,<br />- in whom hypoglycaemia develops gradually,<br />- who are elderly,<br />- after transfer from animal insulin to human insulin,<br />- in whom an autonomic neuropathy is present,<br />- with a long history of diabetes,<br />- suffering from a psychiatric illness,<br />- receiving concurrent treatment with certain other medicinal products (see section 4.5).<br />Such situations may result in severe hypoglycaemia (and possibly loss of consciousness) prior to the patient&#39;s awareness of hypoglycaemia.<br />The prolonged effect of subcutaneous insulin glargine may delay recovery from hypoglycaemia. If normal or decreased values for glycated haemoglobin are noted, the possibility of recurrent,<br />unrecognised (especially nocturnal) episodes of hypoglycaemia must be considered.<br />Adherence of the patient to the dose and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia. Factors increasing the susceptibility to hypoglycaemia require particularly close monitoring and may necessitate dose adjustment. These include:<br />- change in the injection area,<br />- improved insulin sensitivity (e.g., by removal of stress factors),<br />- unaccustomed, increased or prolonged physical activity,<br />- intercurrent illness (e.g. vomiting, diarrhoea),<br />- inadequate food intake,<br />- missed meals,<br />- alcohol consumption,<br />- certain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or adrenocortical insufficiency),</p><p>- concomitant treatment with certain other medicinal products (see section 4.5). Intercurrent illness<br />Intercurrent illness requires intensified metabolic monitoring. In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased. Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food, or are vomiting etc. and they must never omit insulin entirely.<br />Insulin antibodies<br />Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see section 5.1).<br />Handling of the pen<br />Before using SoloStar, the instructions for use included in the package leaflet must be read carefully. SoloStar has to be used as recommended in these instructions for use (see section 6.6).<br />Medication errors<br />Medication errors have been reported in which other insulins, particularly short-acting insulins, have been accidentally administered instead of insulin glargine. Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins.<br />Combination of Lantus with pioglitazone<br />Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and Lantus is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.<br />Excipients<br />This medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. it is essentially<br />&lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A number of substances affect glucose metabolism and may require dose adjustment of insulin glargine.<br />Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics.<br />Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors.</p><p>Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the<br />blood-glucose-lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia.<br />In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. Animal data do not indicate reproductive toxicity.<br />The use of Lantus may be considered during pregnancy, if clinically needed.<br />It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy to prevent adverse outcomes associated with hyperglycemia. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Immediately after delivery, insulin requirements decline rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose control is essential.<br />Breast-feeding<br />It is unknown whether insulin glargine is excreted in human milk. No metabolic effects of ingested insulin glargine on the breast-fed newborn/infant are anticipated since insulin glargine as a peptide is digested into aminoacids in the human gastrointestinal tract. Breast-feeding women may require adjustments in insulin dose and diet.<br />Fertility<br />Animal studies do not indicate direct harmful effects with respect to fertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patient&#39;s ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).<br />Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be considered whether it is advisable to drive or use machines in these circumstances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Hypoglycaemia (very common), in general the most frequent adverse reaction of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement (see section 4.4).<br /><u>Tabulated list of adverse reactions&nbsp;</u></p><p>The following related adverse reactions from clinical investigations are listed below by system organ class and in order of decreasing incidence (very common: &ge;1/10; common: &ge;1/100 to &lt;1/10; uncommon: &ge;1/1,000 to &lt;1/100; rare: &ge;1/10,000 to &lt;1/1,000; very rare: &lt;1/10,000).<br />Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p><img alt="" width="752" height="558" src="data:image/png;base64,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" /></p><p>Description of selected adverse reactions<br />Metabolism and nutrition disorders<br />Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may be life-threatening.<br />In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter-regulation. Generally, the greater and more rapid the decline in blood glucose, the more marked is the phenomenon of counter-regulation and its symptoms (see section 4.4).<br />Immune system disorders<br />Immediate-type allergic reactions to insulin are rare. Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angio-oedema, bronchospasm, hypotension and shock, and may be life-threatening.<br />Eyes disorders<br />A marked change in glycaemic control may cause temporary visual impairment, due to temporary alteration in the turgidity and refractive index of the lens.<br />Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy. However, intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy. In patients with proliferative retinopathy, particularly if not treated with photocoagulation, severe hypoglycaemic episodes may result in transient amaurosis.</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders<br />Lipodystrophy may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions.<br />General disorders and administration site conditions<br />Injection site reactions include redness, pain, itching, hives, swelling, or inflammation. Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.<br />Rarely, insulin may cause sodium retention and oedema particularly if previously poor metabolic control is improved by intensified insulin therapy.<br />Paediatric population<br />In general, the safety profile for children and adolescents (&le;18 years of age) is similar to the safety profile for adults.<br />The adverse reaction reports received from post marketing surveillance included relatively more frequent injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) in children and adolescents (&le;18 years of age) than in adults.<br />Clinical study safety data are not available for children under 2 years.</p><p>Reporting of suspected adverse reactions<br />To report any side effect(s)<br />Saudi Arabia<br />National Pharmacovigilance &amp; Drug Safety Centre (NPC):<br />Fax: +966-11-205-7662<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />Sanofi - Pharmacovigilance:<br />KSA_Pharmacovigilance@sanofi.com</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Insulin overdose may lead to severe and sometimes long-term and life-threatening hypoglycaemia. Management<br />Mild episodes of hypoglycaemia can usually be treated with oral carbohydrates. Adjustments in dose of the medicinal product, meal patterns, or physical activity may be needed.<br />More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, insulins and analogues for injection, long-acting. ATC Code: A10AE04.<br />Mechanism of action<br />Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH. It is completely soluble at the acidic pH of the Lantus injection solution (pH 4). After injection into the subcutaneous tissue, the acidic solution is neutralised leading to formation of micro-precipitates from which small amounts of insulin glargine are continuously released, providing a smooth, peakless, predictable concentration/time profile with a prolonged duration of action.<br />Insulin glargine is metabolised into 2 active metabolites M1 and M2 (see section 5.2).<br />Insulin receptor binding: In vitro studies indicate that the affinity of insulin glargine and its metabolites M1 and M2 for the human insulin receptor is similar to the one of human insulin.<br />IGF-1 receptor binding: The affinity of insulin glargine for the human IGF-1 receptor is approximately 5 to 8-fold greater than that of human insulin (but approximately 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1 receptor with slightly lower affinity compared to human insulin.<br />The total therapeutic insulin concentration (insulin glargine and its metabolites) found in type 1 diabetic patients was markedly lower than what would be required for a halfmaximal occupation of the IGF-1 receptor and the subsequent activation of the mitogenic-proliferative pathway initiated by the IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may activate the<br />mitogenic-proliferative pathway; however, the therapeutic concentrations found in insulin therapy, including in Lantus therapy, are considerably lower than the pharmacological concentrations required to activate the IGF-1 pathway.<br />The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis and enhances protein synthesis.<br />In clinical pharmacology studies, intravenous insulin glargine and human insulin have been shown to be equipotent when given at the same doses. As with all insulins, the time course of action of insulin glargine may be affected by physical activity and other variables.<br />In euglycaemic clamp studies in healthy subjects or in patients with type 1 diabetes, the onset of action of subcutaneous insulin glargine was slower than with human NPH insulin, its effect profile was smooth and peakless, and the duration of its effect was prolonged.<br />The following graph shows the results from a study in patients:</p><p><img src="data:image/png;base64,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" alt="" width="576" height="281" vspace="0" hspace="0" border="0" style="width:576px;height:281px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>*determined as amount of glucose infused to maintain constant plasma glucose levels (hourly mean values)<br />The longer duration of action of subcutaneous insulin glargine is directly related to its slower rate of absorption and supports once daily administration. The time course of action of insulin and insulin analogues such as insulin glargine may vary considerably in different individuals or within the same individual.<br />In a clinical study, symptoms of hypoglycaemia or counter-regulatory hormone responses were similar after intravenous insulin glargine and human insulin both in healthy volunteers and patients with<br />type 1 diabetes.<br />In clinical studies, antibodies that cross-react with human insulin and insulin glargine were observed with the same frequency in both NPH-insulin and insulin glargine treatment groups.<br />Effects of insulin glargine (once daily) on diabetic retinopathy were evaluated in an open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography. No significant difference was seen in the progression of diabetic retinopathy when insulin glargine was compared to NPH insulin.<br />The ORIGIN (Outcome Reduction with Initial Glargine INtervention) study was a multicenter, randomised, 2x2 factorial design study conducted in 12,537 participants at high cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus treated with &le;1 antidiabetic oral agent (88% of participants). Participants were randomised (1:1) to receive insulin glargine (n=6264), titrated to reach FPG &le;95 mg/dl<br />(5.3 mM), or standard care (n=6273).<br />The first co-primary efficacy outcome was the time to the first occurrence of CV death, nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary efficacy outcome was the time to the first occurrence of any of the first co-primary events, or revascularisation procedure (coronary, carotid, or peripheral), or hospitalisation for heart failure.<br />Secondary endpoints included all-cause mortality and a composite microvascular outcome.<br />Insulin glargine did not alter the relative risk for CV disease and CV mortality when compared to standard of care. There were no differences between insulin glargine and standard care for the two co-primary outcomes; for any component endpoint comprising these outcomes; for all-cause mortality; or for the composite microvascular outcome.<br />Mean dose of insulin glargine by study end was 0.42 U/kg. At baseline, participants had a median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9 to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care group throughout the duration of follow-up. The rates of severe hypoglycaemia (affected participants per 100 participant years of exposure) were 1.05 for insulin glargine and 0.30 for standard care group and the rates of confirmed non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard care group. Over the course of this 6-year study, 42% of the insulin glargine group did not experience any hypoglycaemia.<br />At the last on-treatment visit, there was a mean increase in body weight from baseline of 1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the standard care group.<br />Paediatric population<br />In a randomised, controlled clinical study, paediatric patients (age range 6 to 15 years) with type 1 diabetes (n=349) were treated for 28 weeks with a basal-bolus insulin regimen where regular human insulin was used before each meal. Insulin glargine was administered once daily at bedtime and NPH human insulin was administered once or twice daily. Similar effects on glycohemoglobin and the incidence of symptomatic hypoglycemia were observed in both treatment groups, however fasting plasma glucose decreased more from baseline in the insulin glargine group than in the NPH group. There was less severe hypoglycaemia in the insulin glargine group as well. One hundred forty three of the patients treated with insulin glargine in this study continued treatment with insulin glargine in an uncontrolled extension study with mean duration of follow-up of 2 years. No new safety signals were seen during this extended treatment with insulin glargine.<br />A crossover study comparing insulin glargine plus lispro insulin to NPH plus regular human insulin (each treatment administered for 16 weeks in random order) in 26 adolescent type 1 diabetic patients aged 12 to 18 years was also performed. As in the paediatric study described above, fasting plasma glucose reduction from baseline was greater in the insulin glargine group than in the NPH group. HbA1c changes from baseline were similar between treatment groups; however blood glucose values recorded overnight were significantly higher in the insulin glargine/ lispro group than the NPH/regular group, with a mean nadir of 5.4 mM versus 4.1 mM. Correspondingly, the incidences of nocturnal hypoglycaemia were 32% in the insulin glargine / lispro group versus 52% in the NPH / regular group.<br />A 24-week parallel group study was conducted in 125 children with type 1 diabetes mellitus aged 2 to 6 years, comparing insulin glargine given once daily in the morning to NPH insulin given once or twice daily as basal insulin. Both groups received bolus insulin before meals.<br />The primary aim of demonstrating non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and there was a trend to an increase of hypoglycemic events with insulin glargine [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)].<br />Glycohaemoglobin and glucose variabilities were comparable in both treatment groups. No new safety signals were observed in this study.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In healthy subjects and diabetic patients, insulin serum concentrations indicated a slower and much more prolonged absorption and showed a lack of a peak after subcutaneous injection of insulin glargine in comparison to human NPH insulin. Concentrations were thus consistent with the time profile of the pharmacodynamic activity of insulin glargine. The graph above shows the activity profiles over time of insulin glargine and NPH insulin.<br />Insulin glargine injected once daily will reach steady state levels in 2-4 days after the first dose.<br />When given intravenously the elimination half-life of insulin glargine and human insulin were comparable.<br />After subcutaneous injection of Lantus in diabetic patients, insulin glargine is rapidly metabolized at the carboxyl terminus of the Beta chain with formation of two active metabolites M1<br />(21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is the metabolite M1. The exposure to M1 increases with the administered dose of Lantus. The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous&nbsp;injection with Lantus is principally based on exposure to M1. Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of Lantus.<br />In clinical studies, subgroup analyses based on age and gender did not indicate any difference in safety and efficacy in insulin glargine-treated patients compared to the entire study population.<br />Paediatric population<br />Pharmacokinetics in children aged 2 to less than 6 years with type 1 diabetes mellitus was assessed in one clinical study (see section 5.1). Plasma &ldquo;trough&rdquo; levels of insulin glargine and its main M1 and M2 metabolites were measured in children treated with insulin glargine, revealing plasma concentration patterns similar to adults, and providing no evidence for accumulation of insulin glargine or its metabolites with chronic dosing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zinc</p><p>chloride</p><p>Metacresol</p><p>Glycerol<br />Hydrochloric acid (for pH adjustment)</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
Shelf-life after first use of the pen
The medicinal product may be stored for a maximum of 4 weeks not above 30°C and away from direct heat or direct light. Pens in use must not be stored in the refrigerator. The pen cap must be put back on the pen after each injection in order to protect from light.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not in-use pens<br />Store in a refrigerator (2&deg;C-8&deg;C).<br />Do not freeze or place next to the freezer compartment or a freezer pack.</p><p>Keep the pre-filled pen in the outer carton in order to protect from light.&nbsp;</p><p>In-use pens<br />For storage conditions after first opening of this medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type 1 colourless glass cartridge with a black plunger (bromobutyl rubber) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber) containing 3 ml of solution.The cartridge is sealed in a disposable pen injector.<br />Needles are not included in the pack. Packs of 1, 3, 4, 5, 6, 8, 9 and 10 pens.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before first use, the pen must be stored at room temperature for 1 to 2 hours.<br />Inspect the cartridge before use. It must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of water-like consistency. Since Lantus is a solution, it does not require resuspension before use.<br />Lantus must not be mixed with any other insulin or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.<br />Empty pens must never be reused and must be properly discarded.<br />To prevent the possible transmission of disease, each pen must be used by one patient only.<br />Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins (see section 4.4).<br />Before using SoloStar, the instructions for use included in the package leaflet must be read carefully.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sanofi-Aventis Deutschland GmbH,
D-65926 Frankfurt am Main,
Germany
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 Sep 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>